TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23787820

Group type: EXPERIMENTAL
Intervention: K-115 0.05%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-115 0.1%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-115 0.2%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-115 0.4%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-115 0.8%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-115 (all concentrations)
Number of subjects: 100
Study: 21337906

Group type: EXPERIMENTAL
Intervention: Local conjunctival immunotherapy (LCIT) using mixed Dermatophagoides extracts, administered as eyedrops once daily for 6 months.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS) as a control for 6 months.
Number of subjects: 18
Study: 18683852

Group type: EXPERIMENTAL
Intervention: Bacopa monniera (2 x 150 mg KeenMind)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 16437190

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcium, vitamin D, and sex steroids (without pamidronate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients without pamidronate
Number of subjects: 30
Study: 12798977

Group type: EXPERIMENTAL
Intervention: D-fenfluramine (D-FEN) (0.5 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11174123

Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 489
Study: 8868976

Group type: EXPERIMENTAL
Intervention: Clonidine (group 1, n = 22)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Enoximone (group 2, n = 22)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Enalaprilat (group 3, n = 22)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline solution as placebo (control group, n = 22)
Number of subjects: 88
Study: 1319808

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (barbiturates or bed rest)
Number of subjects: 65
Study: 31850717

Group type: EXPERIMENTAL
Intervention: lncRNA expression profiling in advanced resected GA tissues using a lncRNA microarray chip
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Real-time quantitative reverse transcription PCR (qRT-PCR) for 5 differentially expressed lncRNAs (HNF1A-AS1, RP11-62F24.2, GAS5, MALAT1, H19)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Analysis of nearby coding genes (mRNAs)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Differentially expressed lncRNAs
Number of subjects: 47
Study: 28322885

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish CavityShield (CS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish Enamel Pro (EP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish Vanish (V)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of fluoride varnishes
Number of subjects: 18
Study: 26026919

Group type: EXPERIMENTAL
Intervention: Magnesium exposure
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1047
Study: 23356420

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical Management (MM)
Number of subjects: 0
Study: 21551161

Group type: EXPERIMENTAL
Intervention: Bisoprolol (target dose 10 mg o.d.)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Enalapril (target dose 10 mg b.i.d.)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combination of bisoprolol and enalapril
Number of subjects: 1010
Study: 20684146

Group type: EXPERIMENTAL
Intervention: 15% azelaic acid gel applied twice daily for one month
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo gel applied twice daily for one month
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 15% azelaic acid gel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 31
Study: 16938146

Group type: EXPERIMENTAL
Intervention: Undiagnosed ADHD
Number of subjects: 752

Group type: COMPARATOR
Intervention: Non-ADHD controls
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Diagnosed ADHD
Number of subjects: 752
Study: 16359967

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg/d for the first 10 days of the cycle)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spironolactone plus Diane 35 (spironolactone 100 mg/d; Diane 35 is a combination tablet of 2 mg cyproterone acetate and 35 microg ethinylestradiol/d for 9 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Flutamide and spironolactone plus Diane 35
Number of subjects: 80
Study: 12225339

Group type: EXPERIMENTAL
Intervention: Diethylstilboestrol (DES) and aspirin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diethylstilboestrol (DES)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diethylstilboestrol (DES) and Flutamide
Number of subjects: 28
Study: 9706950

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.35 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nalbuphine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% Sodium Chloride (10 mL)
Number of subjects: 0
Study: 7832598

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study: 2226737

Group type: EXPERIMENTAL
Intervention: 5-drug combination therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Palliative treatment regimens
Number of subjects: 92
Study: 417957

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30971600

Group type: EXPERIMENTAL
Intervention: US-guided IJV cannulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: US-guided axillary venous cannulation
Number of subjects: 100
Study: 27607850

Group type: EXPERIMENTAL
Intervention: Nurse-initiated recall cards and medication chart checking at handover
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 534
Study: 24784976

Group type: EXPERIMENTAL
Intervention: 3-month LNS supplementation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 6-month LNS supplementation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 23111657

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 400 mg once daily
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 200 mg once daily
Number of subjects: 137

Group type: COMPARATOR
Intervention: Oral oseltamivir 75 mg twice daily
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 400 mg once daily (in clinically unstable patients)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 200 mg once daily (in clinically unstable patients)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Oral oseltamivir 75 mg twice daily (in clinically unstable patients)
Number of subjects: 137
Study: 21501161

Group type: EXPERIMENTAL
Intervention: rGH treatment in Group A (n = 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: rGH treatment in Group B (n = 5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaccination alone in Group C (n = 7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rGH treatment in Groups A (n = 8) and B (n = 5) combined
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaccination alone in Group C (n = 6)
Number of subjects: 20
Study: 19700872

Group type: EXPERIMENTAL
Intervention: 0.75% tropicamide and 2.5% phenylephrine mixture
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% tropicamide and 10% phenylephrine (alternate application)
Number of subjects: 40
Study: 16722923

Group type: EXPERIMENTAL
Intervention: Evidence-based programme on the management of low back pain, including advice on increasing activity levels and challenging patients' fears and beliefs about their pain.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard in-service training package on the management of common knee pathologies.
Number of subjects: 30
Study: 15319705

Group type: EXPERIMENTAL
Intervention: Propofol (0.2 mg/kg IV bolus)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (Intralipid, Kabi Pharmacia)
Number of subjects: 44
Study: 10981746

Group type: EXPERIMENTAL
Intervention: Intraoperative mild hypothermia (33.5 degrees C, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C, n = 12)
Number of subjects: 24
Study: 9432343

Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 gm/day and lansoprazole (30-180 mg/day) for 2 weeks
Number of subjects: 36
Study: 8342972

Group type: EXPERIMENTAL
Intervention: Mitomycin C alone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mitomycin C and alternating BCG therapy
Number of subjects: 66
Study: 3521480

Group type: EXPERIMENTAL
Intervention: Rimantadine treatment (200 mg/day for 5 days)
Number of subjects: 0
Study: 29670285

Group type: EXPERIMENTAL
Intervention: Normothermic preservation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional static cold storage
Number of subjects: 220
Study: 27185702

Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Gel phantom training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard medical knowledge (Control)
Number of subjects: 54
Study: 24860180

Group type: EXPERIMENTAL
Intervention: LDL cholesterol (measured directly)
Number of subjects: 23738

Group type: EXPERIMENTAL
Intervention: Total number of LDL particles
Number of subjects: 23738

Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein particles
Number of subjects: 23738

Group type: EXPERIMENTAL
Intervention: Number of cholesterol-poor small LDL
Number of subjects: 23738

Group type: EXPERIMENTAL
Intervention: Small very-low-density lipoprotein particles
Number of subjects: 23738

Group type: COMPARATOR
Intervention: Larger cholesterol-rich LDL particles
Number of subjects: 23738

Group type: COMPARATOR
Intervention: All high-density lipoprotein measures
Number of subjects: 23738
Study: 22427342

Group type: EXPERIMENTAL
Intervention: Graphical display decision support system (Navigator™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numerical guidance (control)
Number of subjects: 0
Study: 19897672

Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test
Number of subjects: 138
Study: 19001601

Group type: EXPERIMENTAL
Intervention: 1000 mg of elemental calcium with 400 IU of vitamin D(3) daily
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 36282

Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin D levels
Number of subjects: 36282
Study: 16095421

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT, 80% of 1 repetition maximum [1RM])
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Moderate resistance training (MRT, 60% of 1 repetition maximum [1RM])
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 33
Study: 11923060

Group type: EXPERIMENTAL
Intervention: Adalat OROS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CORAL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CORAL under fed conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: CORAL vs Adalat OROS under fed conditions
Number of subjects: 24
Study: 9893199

Group type: EXPERIMENTAL
Intervention: Lentil ingestion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exposure to steam from cooked lentils
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Allergic reactions to other legumes (chick peas, peas, green beans)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to lentil extract
Number of subjects: 22
Study: 7557504

Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa administered daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa/Carbidopa (1 week administration)
Number of subjects: 0
Study: 2150181

Group type: EXPERIMENTAL
Intervention: Prismashield
Number of subjects: 133

Group type: COMPARATOR
Intervention: Estiseal
Number of subjects: 133

Group type: COMPARATOR
Intervention: Concise
Number of subjects: 133
Study: 7225648

Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: betahistine
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 30646170

Group type: EXPERIMENTAL
Intervention: Positive psychological intervention (6-week series of evidence-based activities to build positive psychological skills)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Neutral control intervention (similarly structured neutral activities)
Number of subjects: 360
Study: 26036956

Group type: EXPERIMENTAL
Intervention: Water extracts of Graptopetalum paraguayense (WGP, 4 g day(-1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24434439

Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin therapy (80 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional atorvastatin therapy (20 mg/day)
Number of subjects: 66
Study: 23128898

Group type: EXPERIMENTAL
Intervention: 0.5 Gy single dose
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 1.0 Gy single dose
Number of subjects: 312
Study: 19460871

Group type: EXPERIMENTAL
Intervention: 1.0 mg of oral lorazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18611212

Group type: EXPERIMENTAL
Intervention: Knowledge about sun safety
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Peer norms
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Peer norms (among ethnic groups)
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Barriers regarding sun exposure
Number of subjects: 1782
Study: 15885165

Group type: EXPERIMENTAL
Intervention: Fuhuang Tablets (4 tablets t.i.d. per os)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Zhining Tablets (4 tablets t.i.d. per os)
Number of subjects: 144
Study: 12204869

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 10579255

Group type: EXPERIMENTAL
Intervention: Acidified enteral feeds (pH = 3.5)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard feeding formula (Vital High Nitrogen, pH = 6.5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acidified enteral feeds
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard feeding formula
Number of subjects: 120
Study: 8796633

Group type: EXPERIMENTAL
Intervention: Peripheral thrombolysis RCTs
Number of subjects: 9
Study: 2064061

Group type: EXPERIMENTAL
Intervention: 0.175% bupivacaine
Number of subjects: 122

Group type: COMPARATOR
Intervention: 0.15% bupivacaine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: greater than or equal to 0.2% bupivacaine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 122
Study: 6364333

Group type: EXPERIMENTAL
Intervention: Tinidazole (4 X 500 mg in one single dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tinidazole (4 X 500 mg in one single dose) for non-responders
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg, 4 times daily, for one week)
Number of subjects: 26
Study: 30769227

Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 564
Study: 29226773

Group type: EXPERIMENTAL
Intervention: Exercise-based intervention (48 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 27112810

Group type: EXPERIMENTAL
Intervention: Combined treatment (CT) with computerized cognitive rehabilitation and right hemifield eye-patching, 15 one-hour sessions
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single treatment (ST) with computerized cognitive rehabilitation, 15 one-hour sessions
Number of subjects: 28
Study: 26009783

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22228392

Group type: EXPERIMENTAL
Intervention: Pain Management Program (PMP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 38
Study: 20080960

Group type: EXPERIMENTAL
Intervention: Conventional composite (Transbond‐XT; 3M Unitek)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ACP‐containing orthodontic composite (Aegis‐Ortho; Harry J. Bosworth Co.)
Number of subjects: 40
Study: 18825438

Group type: EXPERIMENTAL
Intervention: 375 microg interferon beta-1b (sc every other day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 250 microg interferon beta-1b (sc every other day)
Number of subjects: 76
Study: 15839922

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Alfuzosin 15 mg
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study: 11975032

Group type: EXPERIMENTAL
Intervention: Traditional cholecystectomy (TCE)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Minimally invasive cholecystectomy
Number of subjects: 278

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 278
Study: 10333052

Group type: EXPERIMENTAL
Intervention: Enalapril (group 1, n = 7)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoprolol (group 2, n = 6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Reference group without antihypertensive treatment (group 3, n = 9)
Number of subjects: 13
Study: 8600966

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 120
Study: 2012085

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 817

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 817
Study: 6403772

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jejunostomy feedings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eating ad libitum
Number of subjects: 0

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 0
Study: 30829116

Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN) program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Decliners of the HPV vaccine
Number of subjects: 102
Study: 28187915

Group type: EXPERIMENTAL
Intervention: GSK2330672
Number of subjects: 22
Study: 26980340

Group type: EXPERIMENTAL
Intervention: 200 mg once daily celecoxib
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 400 mg once daily celecoxib
Number of subjects: 330

Group type: COMPARATOR
Intervention: 50 mg three times daily diclofenac
Number of subjects: 330
Study: 25053766

Group type: EXPERIMENTAL
Intervention: Music Therapy Group (MTG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No-Music Social Skills Group (SSG)
Number of subjects: 17
Study: 22573676

Group type: EXPERIMENTAL
Intervention: Training on spectral modulation (0.5 cyc/oct; 0 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on temporal modulation (0 cyc/oct; 32 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on upward spectrotemporal modulation (0.5 cyc/oct; 32 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on discrimination tasks
Number of subjects: 0
Study: 18270762

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with intravenous injection of 5 mg/kg of hematoporphyrin monomethyl ether followed by endoscopic irradiation for 40 min at 150 mW/cm².
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no photodynamic therapy).
Number of subjects: 14
Study: 17234503

Group type: EXPERIMENTAL
Intervention: HFCS-sweetened beverages
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucrose-sweetened beverages
Number of subjects: 30
Study: 17328728

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus Azithromycin
Number of subjects: 278

Group type: COMPARATOR
Intervention: Ceftriaxone plus Clarithromycin or Erythromycin
Number of subjects: 278
Study: 15017018

Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment (0.6 mg/kg IV rt-PA, maximum 60 mg over 30 minutes, plus additional rt-PA via microcatheter up to 22 mg over 2 hours)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: rt-PA treatment
Number of subjects: 80
Study: 10792277

Group type: EXPERIMENTAL
Intervention: Continuous chlorambucil (0.1 mg/kg/d for 7 days, repeated every 6 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intermittent chlorambucil (0.3 mg/kg/d for 7 days, repeated every 6 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Continuous chlorambucil
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 46
Study: 8095058

Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 5 x 10(6) IU/m2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 3 x 10(6) IU/m2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PEG IL‐2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 10(6) IU/m2 for 8 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 3 x 10(6) IU/m2 for up to 16 weeks
Number of subjects: 19